MELANOMA OF UNKNOWN PRIMARY
Clinical trials for MELANOMA OF UNKNOWN PRIMARY explained in plain language.
Never miss a new study
Get alerted when new MELANOMA OF UNKNOWN PRIMARY trials appear
Sign up with your email to follow new studies for MELANOMA OF UNKNOWN PRIMARY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major trial tests ipilimumab against standard therapy for High-Risk melanoma
Disease control OngoingThis phase 3 trial tests whether the immunotherapy drug ipilimumab is better than high-dose interferon alfa-2b at preventing melanoma from coming back in patients whose cancer was removed by surgery. Over 1,600 people with high-risk stage III or IV melanoma took part. The study m…
Matched conditions: MELANOMA OF UNKNOWN PRIMARY
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC
-
Can a newer immunotherapy drug keep melanoma from coming back?
Disease control OngoingThis phase III trial compares the drug pembrolizumab (MK-3475) to the current standard treatments—high-dose interferon or ipilimumab—in 1,301 patients with high-risk melanoma that has been surgically removed. The goal is to see if pembrolizumab is better at preventing the cancer …
Matched conditions: MELANOMA OF UNKNOWN PRIMARY
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC
-
PET scans may let melanoma patients stop treatment sooner
Disease control OngoingThis study looks at whether doctors can safely stop standard anti-PD-1 immunotherapy early in people with advanced melanoma that cannot be surgically removed. By using PET/CT scans and tumor biopsies as guides, the goal is to reduce treatment side effects and burden without harmi…
Matched conditions: MELANOMA OF UNKNOWN PRIMARY
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo shows promise in shrinking melanoma before surgery
Disease control OngoingThis study tests whether adding an experimental drug (CMP-001) to the immunotherapy pembrolizumab can better shrink melanoma tumors before surgery and help prevent them from coming back. About 60 adults with stage III or recurrent melanoma that can be surgically removed will rece…
Matched conditions: MELANOMA OF UNKNOWN PRIMARY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC